Kennedy Capital Management, Inc. Cellectis S.A. Transaction History

Kennedy Capital Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$8.01 - $12.84 $372,432 - $597,008	-46,496 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.94 - $16.09 $9,289 - $12,518	778 Added 1.7%	46,496 $586,000
Q2 2021 Aug 16, 2021	SELL	$14.36 - $20.93 $1.02 Million - $1.48 Million	-70,841 Reduced 60.78%	45,718 $707,000
Q1 2021 May 14, 2021	SELL	$18.19 - $33.25 $21,718 - $39,700	-1,194 Reduced 1.01%	116,559 $2.36 Million
Q4 2020 Feb 12, 2021	SELL	$15.87 - $31.64 $12,077 - $24,078	-761 Reduced 0.64%	117,753 $3.19 Million
Q3 2020 Nov 16, 2020	SELL	$15.7 - $20.84 $1.3 Million - $1.72 Million	-82,550 Reduced 41.06%	118,514 $2.19 Million
Q2 2020 Aug 14, 2020	SELL	$8.21 - $21.02 $445,729 - $1.14 Million	-54,291 Reduced 21.26%	201,064 $3.58 Million
Q1 2020 May 15, 2020	BUY	$7.81 - $18.82 $1.99 Million - $4.81 Million	255,355 New	255,355 $2.35 Million

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.